Literature DB >> 33330822

Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines.

Kyoji Ito1, Nobuyuki Takemura1, Fuyuki Inagaki1, Fuminori Mihara1, Norihiro Kokudo1.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related death globally. Clinical guidelines for HCC have been established and revised by many countries and regions. We summarized and compared the treatment algorithms in the updated HCC guidelines established by Japan, China, Hong Kong, the Asian-Pacific Association for the Study of the Liver, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer. Variations in treatment algorithms between the guidelines is inevitable, considering the differences in the prevalence and etiology of HCC, local clinical practice, and medical and insurance systems between countries or regions, and this might be confusing for practitioners worldwide. A comprehensive understanding of the guidelines that are globally available might be useful for future improvement of each guideline. 2020, National Center for Global Health and Medicine.

Entities:  

Keywords:  ablation; surgery; systemic chemotherapy; transcatheter arterial chemoembolization; transplantation

Year:  2020        PMID: 33330822      PMCID: PMC7731415          DOI: 10.35772/ghm.2020.01066

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  34 in total

Review 1.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

2.  US-guided percutaneous alcohol injection of small hepatic and abdominal tumors.

Authors:  T Livraghi; D Festi; F Monti; A Salmi; C Vettori
Journal:  Radiology       Date:  1986-11       Impact factor: 11.105

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

4.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

5.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 6.  Hong Kong consensus recommendations on the management of hepatocellular carcinoma.

Authors:  Ronnie Tung-Ping Poon; Tom Tan-To Cheung; Philip Chong-Hei Kwok; Ann-Shing Lee; Tat-Wing Li; Kwok-Loon Loke; Stephen Lam Chan; Moon-Tong Cheung; Tak-Wing Lai; Chin-Cheung Cheung; Foon-Yiu Cheung; Ching-Kong Loo; Yiu-Kuen But; Shing-Jih Hsu; Simon Chun-Ho Yu; Thomas Yau
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

7.  Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.

Authors:  Gamal Shiha; Alaa Ibrahim; Ahmed Helmy; Shiv Kumar Sarin; Masao Omata; Ashish Kumar; David Bernstien; Hitushi Maruyama; Vivek Saraswat; Yogesh Chawla; Saeed Hamid; Zaigham Abbas; Pierre Bedossa; Puja Sakhuja; Mamun Elmahatab; Seng Gee Lim; Laurentius Lesmana; Jose Sollano; Ji-Dong Jia; Bahaa Abbas; Ashraf Omar; Barjesh Sharma; Diana Payawal; Ahmed Abdallah; Abdelhamid Serwah; Abdelkhalek Hamed; Aly Elsayed; Amany AbdelMaqsod; Tarek Hassanein; Ahmed Ihab; Hamsik GHaziuan; Nizar Zein; Manoj Kumar
Journal:  Hepatol Int       Date:  2016-10-06       Impact factor: 6.047

8.  Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer.

Authors:  Ian D Schnadig; Erik K Fromme; Charles L Loprinzi; Jeff A Sloan; Motomi Mori; Hong Li; Tomasz M Beer
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Authors:  Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  4 in total

1.  Classification of hepatic venous tumor thrombus in hepatocellular carcinoma: should it describe tumor status or predict patient survival?

Authors:  Norihiro Kokudo; Wei Tang; Takashi Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

2.  Determining desire to live among patients with advanced hepatobiliary-pancreatic cancer for whom curative treatment is not indicated.

Authors:  Junko Morishita; Tomoko Inoue
Journal:  Glob Health Med       Date:  2021-06-30

3.  Pulsed Microwave Liver Ablation: An Additional Tool to Treat Hepatocellular Carcinoma.

Authors:  Giacomo Zanus; Giovanni Tagliente; Serena Rossi; Alessandro Bonis; Mattia Zambon; Michele Scopelliti; Marco Brizzolari; Ugo Grossi; Maurizio Romano; Michele Finotti
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

4.  miR-302a-3p Promotes Radiotherapy Sensitivity of Hepatocellular Carcinoma by Regulating Cell Cycle via MCL1.

Authors:  Zifeng Yang; Menglong Zhang; Jian Zhang; Cunkun Chu; Bijuan Hu; Liyin Huang
Journal:  Comput Math Methods Med       Date:  2022-10-10       Impact factor: 2.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.